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Rejection of bone-marrow graft by
recipient-derived cytotoxic Τ lymphocytes against
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"i
Α female patient showed rejection of a T-
lymphocyte-depleted bone-marrow graft from
her phenotypically HLA-identical father. Before
bone-marrow transplantation, there was strong
recipient anti-donor cellular cytotoxic reactivity
directed against several minor histocompatibility
(mH) antigens, including the male-specific H-Y
antigen. After conditioning treatment, no
recipient anti-donor cytotoxic activity could be
detected, and good graft function was shown a
month after transplantation. Thereafter, however,
graft function deteriorated rapidly, while
recipient-derived anti-donor cellular cytotoxic
reactivity, against similar mH antigens,
reappeared. The recipient-derived cytotoxic Τ
lymphocytes could completely inhibit growth of
donor haemopoietic progenitor cells both before
and after bone-marrow transplantation. Thus,
cytotoxic Τ lymphocytes can survive very intensive
conditioning regimens, and residual recipient
cytotoxic Τ lymphocytes directed against mH
antigens expressed on donor haemopoietic
progenitor cells may cause graft rejection after
HLA-identical T-lymphocyte-depleted bone-
marrow transplantation.
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introduction
T-lymphocyte depletion of bone-marrow grafts has been
successfully used to reduce the uicidence of graft-versus-
host-disease after allogeneic HLA-identical bone-marrow
transplantation 1 However, this procedure has resulted in a
higher rate of graft failure 2 5 The mechamsms of graft
failure have not been elucidated, though failure may be due
to immune-mediated rejection of the graft caused by
residual lmmvmocompetent reapient cells that have
survived the pretransplant conditioning regimen
We report here the detailed analysis of graft rejection in a
female bone-marrow transplant recipient of a T-
lymphocyte-depleted graft from her phenotypically HLA-
ldenacal father.
Case-report
4 years before bone-marrow transplantanon, this 32-year-old
woman was treated for Hodgkin lymphoma (rmxed cellularity,
climcal stage IIIB) with radianon therapy and courses of
chemotherapy Α complete remission was obtained 3 years later,
persisting pancytopema developed and she required red-cell and
platelet transfusions Α sample of bone marrow showed a
myelodysplastic syndrome (refractory anaenua with excess of
blasts, FAB type I I I ) 6 Cytogenetic analysis of bone marrow and
blood showed a normal female karyotype Dunng the year before
transplantaoon there were repeated hfe-threatemng infections with
Pseudomonas aeruginosa, and connnuous intravenous antibiotic
treatment was required We decided to carry out allogeneic
bone-marrow transplantation with a graft donated by her
phenotypically HLA-idenücal father The bone-marrow graft was
depleted of Τ lymphocytes by means of munne monodonal
antibodies (anti-CD5 and anti-CD8) and baby rabbit complement
After depletion, the graft contained 20 x 106 nucleated cells and
0 9 x 106 CD3-positive cells per kg body weight The conditioning
regimen for transplantanon consisted of total body Irradiation
(Single dose 9 Gy, dose rate 22 cGy/min, with lung shielding to a
cumulanve dose of 6 Gy, additional shielding of the left kidney to a
cumulaave dose of 3 Gy) on day - 8 before bone-marrow
transplantanon, and cyclophosphamide (60 mg/kg daily) on days
- 5 and - 4 Since her nsk of graft rejecnon was thought to be high
because of pretransplant sensmsanon, the patient was treated with
horse annthymocyte globuhn (ATG, Upjohn, Kalamazoo) 20
mg/kg daily, intravenously on days — 3, — 2, — 1, and on the day of
transplantation (day 0) ATG was continued at a dose of 5 mg/kg
daily every 2 days after transplantation unul day +12
Methylprednisolone (10 mg/kg daily) was given from day - 5 to day
+ 12 Cyclosponn (3 mg/kg daily by connnuous Infusion) was
started on day - 1 and continued to day + 14 From that nme
onwards, cyclosponn was given orally at a dose of 3 mg/kg, three
tunes a day Engraftment was noted on day + 20, and good graft
function was documented on day +36 (neutrophils 9 χ lO^l,
renculocytes 50 per 1000) After day +43, graft funcnon
detenorated, resulting in complete pancytopema on day +64
On day + 85 leukaemic cells were observed in the penpheral
blood and bone marrow The patient's condinon thereafter
detenorated rapidly and she died 105 days after bone-marrow
transplantation
Methods
Cultures of cytotoxic Τ lymphocytes were established by
incubaüng5-10 χ 10* recipient mononuclear cells asresponder cells
with 5-10 x 106 irradiated (20 Gy) donor mononuclear cells as
stimulator cells in RPMI medium plus 15% pooled, prescreened,
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TABLE I—REACTIVITY OF RECIPIENT ΑΝΤΙ DONOR
CYTOTOXICT LYMPHOCYTE LINE ESTABLISHED
BEFORE TRANSPLANTATION
TABLE II—CHROMOSOWIE ANALYSIS OF RECIPIENT CELLS AND
ESTABLISHMENT OF RECIPIENT DERIVED CYTOTOXIC
Τ LYMPHOCYTE (CTL) LINES
Target
cells
Donor
Recipient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22at
22b
23af
23b
Sex
Μ
F
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
F
F
F
F
F
F
F
F
F
F
Μ
F
F
F
HLA antigen sharing
ΑΙ, Α2, Β8, Bw61, Cw2, Cw7, DR3, DR4
AI, A2, B8, Bw61, Cw2, Cw7, DR3, DR4
A1.DR3
A1,B8,DR3
A1,A2,B8,DR3,DR4
A1,B8,DR3
AI, DR4
AI
AI
A2
DR3
None
None
A2
A2
A2
A2
AI, A2, B8, Cw7, DR3
Al,A2,Cw2
A1,A2,B8,DR3
A1,B8,DR3
A1,B8,DR3
A1,B8,DR3
AI, Cw2
AI, Cw2
A1,DR4
AI, DR4
%
specific
lysis*
95
0
83
98
90
94
81
46
68
2
1
0
3
3
1
0
30
12
16
43
34
35
18
87
6
55
4
·% specific lysis of phytohaemagglutimn stimulated blasts in "Cr release
assay
tTarget cells 22 a and b 23 a and b were obtained from pairs of genotypically
HLA identical siblings
heat-inacnvated human AB serum After 6 days of culture,
responder cells were harvested and used in a cell-mediated
lympholysis assay' Alternatively, responder cells were expanded by
resnmulanon with 106 lrradiated (20 Gy) mononuclear cells or
irradiated (50 Gy) Epstein-Barr-virus (EBV) transformed Β cells
from the donor (5 χ 105 cells per 10s responder cells) in RPMI with
20% T-cell growth factor (Biotest, Offenbach, West Germany)
plus 15% serum Fresh medium was added every 3 or 4 days and
new stimulator cells were added once a week In this way,
prohferating cell lines were established that could be kept in culture
for many weeks Cytotoxic reacüvity was tested in a chromium-51-
release assay7 Surface marker analysis with monoclonal anübodies
against CD3, CD4, CD8, or CD16 anngens was carned out as
descnbed previously8
Cell-mediated cytotoxicity against haemopoienc progerutor cells
was mvesogated as descnbed previously 9 Bnefly, 5 x 105 effector
cells were incubated with "5 x 10* bone-marrow mononuclear cells
in 0 5 ml medium (RPMI 1640 plus 15% serum) for 4-18 h
Thereafter, the cell mixiure was washed once in RPMI plus 15%
serum and cultured for the myeloid (CFU-GM), erythroid
(CFU-E/BFU-E), and the multipotent (CFU-GEMM)
haemopoietic progemtor cells The percentage growth in these
cultures was calcula £ed as the ratio of colorues grown in the presence
of effector cells to colorues observed in untreated control
cultures
Results
The paotnt and her father had identical HLA phenotypes,
as defined by serological assue typrng techniques Typing of
other ianuly members showed that the patient had inhented
the AI, B8, Bw6, Cw7, DR3, DQw2 haplotype from her
mother and shared the A2, Bw61, Bw6, Cw2, DR4, DQw3
haplotype with her father There was no reactivity in
crossmatches between leucocytes, platelets, and
Dayof
sampling
-10
- 6
+28
+35
+ 64
+ 88
+ 96
+ 105
Chromosome analysis
100% XX
ND
ND
100% XY
100% XY
39% XY, 11% XX, 50% XOt
45% XX, 55% XOt
100% XOt, - 7 , - 2 1 , 6q
% specific lysis'
of CTL hne with
Donor
cells
81
79
11
4
39
26
48
36
Recipient
cells
0
1
2t
Ot
5
3
0
4
"In "Cr release assay with phytohaemagglutmin stimulated blasts as target cells
effectot/target ratio 40/1
tPhenotype CD3+ CD4+ CD8 CD16 Phenotype of all other cytotoxic
Τ lymphocyte lines CD3 + CD4 CD8+ CD16
tRecipient ongm shown by polymorphism on chromosome 3
ND —notdone
erythrocytes from the recipient and serum from the donor or
the opposite combinaaons However, there was streng
recipient ann-donor reactivity in both the rmxed
lymphocyte reaction (relative response mdex 78%) and the
cell-mediated lympholysis assay, no donor anti-recipient
reactivity was observed
By means of a panel of target cells, we showed that the
anü-donor cytotoxic T-lymphocyte hne estabhshed from
the recipient before transplantaaon had cytotoxic reactivity
against several minor histocompanbihty (mH) antigens,
including the male-specific antigen H-Y (table i), there was
substannal lysis of all HLA-Al-posiOve male target cells
The male specificity of the cytotoxic T-lymphocyte hne was
confirmed by means of a subclone (data not shown)
However, substannal lysis of several female target cells was
also observed, lndicanng additional cytotoxic reactivity
against other mH anügens This reacnvity seemed to be
restncted by the HLA A1/B8 or HLA A2 antigens
Differential lysis of target cells from pairs of genotypically
HLA-idenncal sibhngs confirmed that these reacnvities
were directed against mH antigens
TABLE III—REACTIVITY OF ΑΝΤΙ DONOR CYTOTOXIC
Τ LYMPHOCYTE LINES ESTABLISHED BEFORE AND AFTER
TRANSPLANTATION (BMT)
Target
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
4V
42
43
Sex
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
Μ
F
F
F
F
F
F
F
F
F
F
Η LA antigen Sharing
A1,B8,DR3
A1,B8,DR3
A2, DR4
A2
A2,DR4
A2
A2
A2,DR3
A2,Cw7
Cw7, DR4
Al,B8,Cw7,DR3
A1,B8,DR3
A1,B8,DR3
AI, Cw7
A2, B8, DR3
A2, Cw2
A2
A2.DR4
DR3
None
% specific lysis
Before BMT
>40
>40
15-40
15-40
1^40
>40
15-40
15-40
<15
<15
>40
>40
>40
<15
>40
15^0
<15
<15
<15
<15
After BMT
>40
>40
15-40
1S40
<15
1^40
15-40
<15
<15
<15
>40
>40
>40
<15
>40
<15
15-40
<15
<15
<15
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TABLE IV—GROWTH OF HAEMOPOIETIC PROGENITOR CELLS
(HPC) AFTER INCUBATION WITH ANTI-DONOR CYTOTOXIC
T-LYMPHOCYTE (CTL) LINES*
—
Pretransplant CTL hne
CFU-GM
CFU-E
BFU-E
CFU-GEMM
Post-transplant CTL hne
CFU-GM
CFU-E
BFU-E
CFU-GEMM
% colony growth of
untreated bone-marrow cells
Donor HPC
6
40
12
0
2
20
11
0
Controlf HPC
102
97
114
100
96
86
88
90
* Effector/target ratio 10/1
tBone marrow from a female donor whose phytohaemagglutimn stimulated blasts
were not lysed in the "Cr-release assay
Chromosome analysis10 of recipient bone marrow and
peripheral blood cells after bone-marrow transplantation is
presented in table π. During the first 60 days only
donor-type metaphases could be detected, whereas from
day 88 onwards there was progressive loss of cells with
donor-type metaphases. They were replaced by recipient-
type cells with normal metaphases and leukaemic cells with
an XO karyotype. The latter cells were also of recipient
origin as shown by chromosome polymorphism.
After total body irradiation 6 days before transplantation
anti-mH reacüvity was still found (table II) on Stimulation of
recipient mononuclear cells with irradiated donor
mononuclear cells. No anti-donor lymphocyte lines could
be generated from the recipient on days - 4 , —1, +8 , + 12,
+ 15, or +21. However, from day +28 to day +105,
T-lymphocyte lines could be established from the recipient
after specific Stimulation with donor cells (table II). Specific
anti-donor cytotoxicity was observed on days + 64, + 88,
+ 96, and + 105. All these lines were of recipient origin, as
shown by their normal 46XX karyotype on chromosome
analysis.
Α comparison of the cytotoxic reactivity of T-lymphocyte
lines established before and after transplantation is shown in
table III. HLA-restricted anti-mH reactivity could be
shown both before and after transplantation. The cytotoxic
reactivity patterns obtained before and after transplantation
were similar, although there were some differences in
HLA-A2-restricted anti-mH reactivity (table in).
There was strong inhibition of donor CFU-GM,
CFU-E, BFU-E, and CFU-GEMM colony growth on
incubation with anti-donor cytotoxic T-lymphocyte lines
established before and after transplantation, whereas no
such inhibition was observed with haemopoietic progenitor
cells from an unrelated individual. Thus, the cytotoxic
reactivity of the recipient cells against donor haemopoietic
progenitor cells was antigen specific (table iv).
Discussion
We have investigated the mechanism of graft failure in a
patient who underwent T-lymphocyte-depIeted bone-
marrow transplantation. During pretransplant analysis this
patient was found to be immunised against several mH
antigens. Anti-mH activity was still detectable after total
body irradiation, but it disappeared after completion of
the immunosuppressive conditioning regimen. Good
graft function was demonstrated about a month after
transplantation, and routine cytogenetic analysis at this time
showed only donor-type metaphases. However, even during
this period of good engraftment of donor cells, T-
lymphocyte lines of recipient origin could be established
after specific in-vitro Stimulation with donor cells. At first
this anti-donor response was merely proliferative. However,
at the time of clinical graft failure, host-derived cytotoxic Τ
lymphocytes were able to lyse donor Τ cells and
haemopoietic progenitor cells. Finally, only autologous
(host-derived) normal and leukaemic cells were detectable
and the patient died.
Cytotoxic T-lymphocyte lines established before and
after bone-marrow transplantation showed several anti-mH
cytotoxic specificities, including the male-specific H-Y
antigen. The cytotoxic reactivity of the effector cells was
similar before and after transplantation, although there were
some differences in HLA-A2-restricted specificities
afterwards. In a previous female patient treated by our
group11 an HLA-restricted H-Y-specific T-cell response
from the peripheral blood could be elicited after rapid
rejection of an unmodified bone-marrow graft from her
genotypically HLA-identical brother. These observations
and others1213 show that immunocompetent cells can
survive intensive conditioning regimens. In allogeneic
bone-marrow transplantation with undepleted grafts,
residual immunocompetent cells in the recipient, capable of
rejecting the graft, may be suppressed or eliminated by
donor Τ lymphocytes present in the graft. Indeed, the
engraftment-promoting effect of Τ lymphocytes has been
shown in several animal models.1415 When the bone-
marrow graft is depleted of Τ lymphocytes to prevent
graft-versus-host disease, this immunosuppressive effect of
donor Τ lymphocytes is also lost, resulting in a greater risk of
graft rejection.2"5 This report shows that prior sensitisation
of the recipient against donor antigens may even further
raise the risk of graft rejection.16
We have identified the expression of several mH antigens
on haemopoietic progenitor cells and shown that they can be
recognised by cytotoxic Τ lymphocytes as possible target
structures. Since mH antigens seem to be differentially
expressed on haemopoietic progenitor cells,17 not all mH
antigens may be equally important in bone-marrow graft
rejection. The recipient cytotoxic Τ lymphocytes directed
against mH antigens in our patient before and after
transplantation could completely inhibit growth of donor
haemopoietic progenitor cells; this anti-mH reactivity was
therefore the cause of the graft rejection.
In conclusion, this study has shown that it may not be
possible to eradicate all immunocompetent cells in
recipients of bone-marrow transplantation, even with highly
immunosuppressive conditioning regimens. Furthermore,
complete chimerism, as determined by cytogenetic analysis
of bone marrow and peripheral blood cells after
transplantation, does not exclude the presence of residual
immunocompetent recipient Τ cells capable of graft
rejection. These recipient Τ cells can be detected in vitro by
specific Stimulation with donor cells. Finally, cytotoxic Τ
cells against mH antigens that are present before bone-
marrow transplantation can be directly involved in the
rejection of HLA-identical bone-marrow grafts.
Pretransplant immunisation, for example by blood
transfusions, may be an important factor in this process.
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